LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye d... LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.405 | 1.65644171779 | 24.45 | 25.85 | 24.01 | 77462 | 25.01320479 | CS |
4 | 1.035 | 4.34508816121 | 23.82 | 27.46 | 23.51 | 105472 | 25.24403665 | CS |
12 | -11.605 | -31.8294020845 | 36.46 | 38.77 | 21.34 | 142042 | 28.40068666 | CS |
26 | 2.565 | 11.5074024226 | 22.29 | 38.93 | 19.9001 | 154361 | 27.14048153 | CS |
52 | 8.875 | 55.5381727159 | 15.98 | 38.93 | 14.42 | 156802 | 23.22354024 | CS |
156 | 8.875 | 55.5381727159 | 15.98 | 38.93 | 14.42 | 156802 | 23.22354024 | CS |
260 | 8.875 | 55.5381727159 | 15.98 | 38.93 | 14.42 | 156802 | 23.22354024 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions